Opthea Limited Sponsored ADR (OPT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Opthea Limited is set to showcase its promising treatment for wet age-related macular degeneration, sozinibercept, at the upcoming FLORetina Congress in Italy. The drug, being tested in pivotal Phase 3 trials, aims to enhance the efficacy of existing therapies and improve vision outcomes. This presentation positions Opthea as a key player in advancing retinal disease treatments.
For further insights into OPT stock, check out TipRanks’ Stock Analysis page.